The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine.
We analyzed the evolution of the ophthalmopathy associated with Graves' hyperthyroidism in 45 patients treated with two different antithyroid drug regimens. Group A patients (n = 31) received either methimazole (40-100 mg daily) or propylthiouracil (400-900 mg daily) combined with T3 daily throughout treatment. Group B patients (n = 14) were treated with conventional regimen with lower doses of either methimazole (5-25 mg daily) or propylthiouracil (50-300 mg daily) and no T3 addition. Eye signs and proptosis measurement were evaluated just before the beginning of the treatment and compared with the results after antithyroid drug withdrawal. Improvement of the eye signs considered on grounds of the NOSPECS classification was greater in group A than group B (p less than 0.01). Also, the decrease in proptosis measurement was greater (p less than 0.01) in patients treated with combined regimen (21.5 +/- 2.4 mm to 20.4 +/- 2.3 mm) than in patients receiving conventional therapy (20.4 +/- 1.6 mm to 20.0 +/- 1.7 mm). Serum thyroglobulin concentrations did not correlate with either the severity or the evolution of the ophthalmopathy. Negative serum antithyroglobulin antibody (TgAb) was associated with the improvement of the ophthalmopathy that was noted in 24 out of 27 patients (Chi-Square = 5.84; p less than 0.001). Thus, serum TgAb levels might have some connection with progression of eye signs but serum Tg concentration does not. Our study suggests that in most patients the transition from hyperthyroidism to euthyroidism induced by antithyroid drug therapy is associated with the improvement of the Graves' ophthalmopathy. However, no marked difference can be drawn between the two treatment regimens.
Bromberg
N
N
Department of Endocrinology, Hospital Servidor Publico Estadual de Sao Paulo, Brazil.
Romaldini
J H
JH
Werner
R S
RS
Sgarbi
J A
JA
Werner
M C
MC
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000097:blood; D004359:Drug Therapy, Combination; D005128:Eye Diseases / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008713:Methimazole / Q000008:administration & dosage*; D008875:Middle Aged; D011441:Propylthiouracil / Q000008:administration & dosage*; D013954:Thyroglobulin / Q000097:blood / Q000276:immunology; D014284:Triiodothyronine / Q000008:administration & dosage*
D001323:Autoantibodies; D014284:Triiodothyronine; D008713:Methimazole; D011441:Propylthiouracil; D013954:Thyroglobulin